Polθ is essential for cell survival in HR-deficient cancers (e.g., those associated with brca1 or brca2 mutations) by compensating for the loss of HR-mediated repair [48,104], pointing to Polθ as a potentially promising therapeutic target. This evidence concerns the gene BRCA2 and cancer.